top of page
KRAS Cancer News & Updates
Why AML Treatments Don’t Always Work—and What This Study Reveals About KRAS, NPM1, and Monocytic Resistance
By KRAS Kickers – Cancer Knowledge + Research + Advocacy = Survivorship 📅 May 2025 | 🧬 Published in Blood Cancer Discovery 🔬...
Terri Conneran KRAS Kickers
May 22
LGSOC Cancer Treatment FDA Fast Tracked
Low-Grade Serous Ovarian Cancer (LGSOC)Â is a rare, slow-growing type of ovarian cancer. It starts in the cells lining the ovaries, fallopian tubes, or peritoneum ...
Lung & Pancreatic cancer Patient Knowledge of Research
KRAS Kickers is a cancer patient-led nonprofit organization that shares Knowledge of publicly available Research to empower patients and caregivers to Advocate for Survivorship.
Our goal to kick cancer's KRAS!
Essential Guide to Cancer Biomarkers For Cancer Patients
Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus.
Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference.
Biomarkers provide the insights as to what is driving the cancer.
Terri Conneran KRAS Kickers
Apr 22
NEW combination trial arm of RMC-9805 plus RMC-6236
Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...
fireflyannf
Apr 7
Black Diamond trial of BDTX-4933
A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...
fireflyannf
Apr 7
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...
fireflyannf
Apr 7
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS At MD...
fireflyannf
Apr 7
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors
Phase 1 trial, 230 patients Trial opened April 2024 in Australia Expanded to US Locations in September 2024  “ Brief Summary This is a...
fireflyannf
Apr 7
PROSPER trial for KRAS G12C mutations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)  Phase 1/2 - 403 patients to enroll Opened in...
fireflyannf
Apr 7
What Is ASCO Conference—And Should Cancer Patients Care?
💡 Why It Matters to Patients:
Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you:
-Ask better questions -
-Stay ahead of the curve -
-Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpr
Precision Medicine has Empowered Cancer Patients
One of the patient voices from this documentary is Terri Conneran: Empowering the Patients For Precision Cancer Advocacy In the documentary, powerful stories from patients, industry experts, and healthcare providers about how precision medicine has empowered their healthcare decisions, providing renewed hope .
Why AML Treatments Don’t Always Work—and What This Study Reveals About KRAS, NPM1, and Monocytic Resistance
By KRAS Kickers – Cancer Knowledge + Research + Advocacy = Survivorship 📅 May 2025 | 🧬 Published in Blood Cancer Discovery 🔬...
bottom of page